Clinical Trials Face More FDA Scrutiny; DoJ Settlements Focus On Data Use
Executive Summary
FDA is ratcheting up enforcement of clinical trial sites, conducting more inspections during the course of pivotal studies and issuing more warning letters to investigators.
You may also be interested in...
J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
The government charged J&J with bribing doctors in Greece, Poland and Romania to order or prescribe its products; the $70 million settlement includes a deferred prosecution agreement.
Foreign Clinical Trials: FDA Oversight To Include More Training, Data Collection
Changes to FDA's policy for monitoring foreign clinical trials appear imminent after the Department of Health and Human Services Inspector General recommended the agency increase its oversight of data gathered outside the U.S
AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges
AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement